Thomas D. Willis
Directeur Général chez Sequenta, Inc.
Profil
Thomas D.
Willis was the founder of ParAllele BioScience, Inc. (founded in 2001) where he held the title of Chief Scientific Officer until 2013, and Sequenta, Inc. (founded in 2007) where he held the title of Chief Executive Officer.
Currently, he is a Partner at IIF Management Co. LLC since 2017.
He has also worked as a Director at Boreal Genomics, Inc. and SpinX Technologies SA. In 2005-2007, he was the Vice President-DNA Product Marketing at Affymetrix, Inc. and was a Principal at Stanford Genome Technology Center from 1996 to 2013.
Dr. Willis has a graduate and doctorate degree from Stanford University and an undergraduate degree from Yale University.
Postes actifs de Thomas D. Willis
| Sociétés | Poste | Début |
|---|---|---|
Sequenta, Inc.
 Sequenta, Inc. BiotechnologyHealth Technology Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA. | Directeur Général | 18/08/2010 |
IIF Management Co. LLC
 IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Private Equity Investor | 01/01/2017 |
Anciens postes connus de Thomas D. Willis
| Sociétés | Poste | Fin |
|---|---|---|
SpinX Technologies SA
 SpinX Technologies SA Medical SpecialtiesHealth Technology SpinX designs and develops products which exploit its innovative adaptive microfluidics technology. The firm's platform offers a fully integrated solution which drastically reduces manual work, while avoiding complex and costly robotics, and can be used in a wide variety of applications, from drug discovery to consumer diagnostics. The reduced consumption of samples, reagents and other consumables enables increased throughput and results in significant cost savings. Additionally, the platform enables sophisticated interleaved liquid handling and detection steps not possible with other systems. SpinX is an international, multidisciplinary - but highly focused - team with world-class competences in microfludics, opto-electronics, molecular biology, biochemistry and software. The founders of SpinX Technologies, Bart Van de Vyver, Ph.D and Piero Zucchelli, Ph.D., worked together for 10 years on various research projects at CERN, the European Organization for Nuclear Research. They have conducted leading-edge academic research in particle physics and instrumentation and managed numerous state-of-the-art research projects. The SpinX Board of Directors and Advisory Board include experts from Europe and the United States, from a variety of backgrounds and disciplines covering drug discovery, diagnostics, microfluidics and physics. | Directeur/Membre du Conseil | 12/08/2010 |
| AFFYMETRIX, INC. | Sales & Marketing | 01/01/2007 |
Boreal Genomics, Inc.
 Boreal Genomics, Inc. Medical SpecialtiesHealth Technology Boreal Genomics, Inc. develops and markets DNA and RNA purification, enrichment, and detection equipment and tools. It provides research tools and developing diagnostic tests based on non invasive tumor profiling and monitoring of cancer. The company’s OnTarget platform performs sensitive genomic analysis of cell free DNA in plasma to detect and quantify mutations in tumor derived circulating nucleic acids. The company was founded by Andre Marziali, Jason Donald Thompson, Joel Pel and David J. Broemeling in 2007 and is headquartered in Vancouver, Canada. | Président | - |
| Stanford Genome Technology Center | Corporate Officer/Principal | - |
ParAllele BioScience, Inc.
 ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Directeur Général | - |
Formation de Thomas D. Willis
| Stanford University | Doctorate Degree |
| Yale University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
ParAllele BioScience, Inc.
ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Commercial Services |
Sequenta, Inc.
Sequenta, Inc. BiotechnologyHealth Technology Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
Boreal Genomics, Inc.
Boreal Genomics, Inc. Medical SpecialtiesHealth Technology Boreal Genomics, Inc. develops and markets DNA and RNA purification, enrichment, and detection equipment and tools. It provides research tools and developing diagnostic tests based on non invasive tumor profiling and monitoring of cancer. The company’s OnTarget platform performs sensitive genomic analysis of cell free DNA in plasma to detect and quantify mutations in tumor derived circulating nucleic acids. The company was founded by Andre Marziali, Jason Donald Thompson, Joel Pel and David J. Broemeling in 2007 and is headquartered in Vancouver, Canada. | Health Technology |
SpinX Technologies SA
SpinX Technologies SA Medical SpecialtiesHealth Technology SpinX designs and develops products which exploit its innovative adaptive microfluidics technology. The firm's platform offers a fully integrated solution which drastically reduces manual work, while avoiding complex and costly robotics, and can be used in a wide variety of applications, from drug discovery to consumer diagnostics. The reduced consumption of samples, reagents and other consumables enables increased throughput and results in significant cost savings. Additionally, the platform enables sophisticated interleaved liquid handling and detection steps not possible with other systems. SpinX is an international, multidisciplinary - but highly focused - team with world-class competences in microfludics, opto-electronics, molecular biology, biochemistry and software. The founders of SpinX Technologies, Bart Van de Vyver, Ph.D and Piero Zucchelli, Ph.D., worked together for 10 years on various research projects at CERN, the European Organization for Nuclear Research. They have conducted leading-edge academic research in particle physics and instrumentation and managed numerous state-of-the-art research projects. The SpinX Board of Directors and Advisory Board include experts from Europe and the United States, from a variety of backgrounds and disciplines covering drug discovery, diagnostics, microfluidics and physics. | Health Technology |
| Stanford Genome Technology Center | |
IIF Management Co. LLC
IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Finance |
